Cephalothin Sodium
CEFALOTIN SODIUM · CEPHALOTHIN SODIUM SALT · CEPHALOTHIN ACID · 38253 · Coaxin · Keflin · Seffin · Microtin
식별자 및 물리적 특성
| CAS No. | 58-71-9 |
|---|---|
| 분자식 | C16H15N2NaO6S2 |
| 평균 분자량 | 418.4 g/mol |
| 단동위원소 질량 | 418.02692248 g/mol |
| SMILES | CC(=O)OCC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)Cc3cccs3)[C@H]2SC1.[Na+] |
| InChIKey | VUFGUVLLDPOSBC-XRZFDKQNSA-M |
| PubChem CID | 23675321 |
| ChEMBL | CHEMBL1632 |
| ChEBI | CHEBI:3542 |
| EC No. | 200-394-6 |
| DTXSID | DTXSID30891362 |
화학 및 물리적 성질
| 극성 표면적 | 169 |
|---|---|
| 수소 결합 공여자 수 | 1 |
| 수소 결합 수용자 수 | 8 |
| 회전 가능 결합 수 | 7 |
| 무거운 원자 수 | 27 |
| 형식 전하 | 0 |
| 복잡도 | 686 |
| Human Drugs | FDA approved drugs -> Active ingredient |
| Collision Cross Section | 183.1 Ų [M+Na]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards] |
| 녹는점 | 240°C |
| 저장 조건 | Inert atmosphere,2-8°C |
| 용해도 | H2O: 50 mg/mL, 투명, 희미한 노란색 |
| 물리적 상태 | Solid |
| 색상 | 흰색에서 황백색까지 |
| 용해도 | 158MG/L |
| Merck | 13,1994 |
| BRN | 4120706 |
| 안정성 | 흡습성 |
| InChI | InChI=1/C16H16N2O6S2.Na/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23)/t12-,15-/s3 |
| InChIKey | XXDPRVHYESWPEX-JQWYMVCGNA-N |
| SMILES | C(C1=C(CS[C@]2([H])[C@@H](C(N21)=O)NC(=O)CC1SC=CC=1)COC(=O)C)(=O)O.[Na] |&1:5,7,r| |
화학적 성질
Crystalline
안전 및 규제
| GHS 분류 | DangerH317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin]P233, P260, P261, P271, P272, P280, P284, P302+P352, P304+P340, P321, P333+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 58 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| 규제 정보 | Status: Active Update: 22-03-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/231805-Thia-1-azabicyclo4.2.0oct-2-ene-2-carboxylic acid, 3-(acetyloxy)methyl-8-oxo-7-(2-thienylacetyl)amino-, monosodium salt, (6R,7R)-: Does not have an individual approval but may be used under an appropriate group standard |
| 기타 안전 정보 | IMAP assessments - 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, monosodium salt, (6R-trans)-: Environment tier I assessment |
| Hazard Classes and Categories | Skin Sens. 1 (100%) |
| 수질 위해 등급(WGK) | 2 |
| RTECS 번호 | XI0388300 |
| 독성 | LD50 in mice, rats (mg/kg): >20000, >10000 orally5670, 7716 i.p. (Kuramoto) |
| 관세 코드 | 29419000 |
| 위험 문구(R) | 42/43 |
| 위험 표시 | Xn,Xi |
| 안전 문구(S) | 22-36/37 |
| 위험 등급 | Resp. Sens. 1Skin Sens. 1 |
| 저장 분류 | 11 - Combustible Solids |
용도
개요
Cefalothin is a β-lactam cephalosporin antibiotic. It inhibits the growth of various Gram-positive and Gram-negative bacteria, including several strains of S. pyogenes, S. aureus, C. tetani, N. gonorrhoeae, Salmonella, and Shigella (MICs = 0.1-0.2, 0.312-0.625, 0.078, 1.25, 1.56-6.25, and 3.12-12.5 μg/ml, respectively). Cefalothin binds to E. coli penicillin-binding proteins (PBPs; IC50s = S. pyogenes, D. pneumoniae, and S. aureus. Formulations containing cefalothin were previously used in the prophylaxis and treatment of bacterial infections.
용도
Cephalothin sodium salt is used to study the mechanism of liposome encapsulated antibiotics1, strategies for co-opting β-lactamases of Gram-negative bacteria for treatment of antibiotics2, and for immunology studies in relation to antibiotics.3 It is used to study the effect of expression, binding and inhibition of penicillin-binding proteins especially PBP6 on bacterial cell wall mucopeptide synthesis.
일반 설명
Cephalothin, along with cephaloridine, was the first of the synthetic cephalosporin C class antibiotics to be introduced clinically. It was synthesized from 7-amino-cephalosporanic acid by Lilly Research Laboratories in 1962. Cephalothin shows strong activity against gram-positive and gram-negative bacteria and Leptospira, including benzylpenicillin-resistant strains. It has been used intravenously and intramuscularly to treat a variety of infections caused by Staphylococcus, Streptococcus, Escherichia coli, and Neisseria. The drug is metabolized in vivo, and the metabolite, deacetylcephalothin, is almost inactive.